Moderna has announced quarterly losses that exceeded expectations due to expenses related to vaccine development for COVID-19. According to the company, net losses in the third quarter amounted to 336 million dollars, which was three times higher than analysts' forecasts. Moderna noted that research and development expenses were higher than anticipated. "We are proud of the results achieved by our team in the fight against the pandemic. However, to achieve these results, we have invested substantial efforts and resources, which has led to significant financial expenditures," said the chairman of the company. He also added that Moderna remains resolutely committed to providing vaccines to people around the world and will continue to work in this direction.
Moderna Reports Greater Than Expected Quarterly Losses
Moderna announced on Friday that its quarterly losses exceeded expectations due to costs associated with its ongoing efforts.
